Old Web
English
Sign In
Acemap
>
authorDetail
>
R Kunka
R Kunka
GlaxoSmithKline
Nausea
Vomiting
Medicine
Pharmacology
Neutropenia
5
Papers
101
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
1998
Clinical Cancer Research
S. G. Eckhardt
Sharyn D. Baker
John R. Eckardt
T G Burke
D L Warner
J G Kuhn
G. Rodriguez
S. Fields
Allison Thurman
Lon Smith
M L Rothenberg
White L
P Wissel
R Kunka
S. DePee
D Littlefield
H. A. Burris
D. D. Von Hoff
Eric K. Rowinsky
Show All
Source
Cite
Save
Citations (34)
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
1998
British Journal of Cancer
L Paz-Ares
R Kunka
D DeMaria
Jim Cassidy
M. Alden
P. Beranek
Stanley B. Kaye
D Littlefield
D Reilly
S. DePee
P. Wissel
C. Twelves
P. J. O'Dwyer
Show All
Source
Cite
Save
Citations (21)
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
1996
British Journal of Cancer
C. J. H. Gerrits
G. J. Creemers
Jan H. M. Schellens
P. Wissel
A. S. T. Planting
R Kunka
K. Selinger
M. de Boer-Dennert
Y. Marijnen
M Harteveld
Jaap Verweij
Show All
Source
Cite
Save
Citations (44)
PhaseIandpharmacological study ofthenew topoisomerase Iinhibitor G1147211, using a daily x5intravenous administration
1996
R Kunka
K. Selinger
M deBoer-Dennert
Y. Marijnen
M Harteveld
Show All
Source
Cite
Save
Citations (0)
928 Phase I trial of the topoisomerase I inhibitor GG211 as a 72-hour infusion
1995
European Journal of Cancer
P. O’Dwyer
L. Pas-Arez
R Kunka
D DeMaria
Jim Cassidy
Stanley B. Kaye
S. DePee
D Littlefield
K. Selinger
P. Beranek
J. Graham
P. Wissel
Show All
Source
Cite
Save
Citations (2)
1